Industry

BELLEVUE, Wash.–(BUSINESS WIRE)–#CurvaFixImplant—CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the completion of the 100th surgical procedure using the CurvaFix® IM Implant to repair a pelvic fragility fracture for a geriatric patient at University Hospital at the University of Missouri in Columbia, Mo. The surgery was performed by … [Read more…]

BURLINGAME, Calif.–(BUSINESS WIRE)–#DepressionTreatment—Magnus Medical, Inc., a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, today announced it received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the SAINTTM Neuromodulation System for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory … [Read more…]

ROCKVILLE, Md.–(BUSINESS WIRE)–#biotech–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, … [Read more…]

Study shows VivAer was effective in reducing symptoms of nasal airway obstruction for patients with both dynamic and static nasal valve collapse SUNNYVALE, Calif.–(BUSINESS WIRE)–#ENT—Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that JAMA Otolaryngology – Head & Neck Surgery … [Read more…]

FREMONT, Calif.–(BUSINESS WIRE)–Cyber-physical identity access management and security leader AlertEnterprise revealed the addition of its new Asset Governance module to their Guardian security convergence platform. AlertEnterprise Asset Governance connects individual digital identities to physical assets such as keys, computers and company vehicles helping organizations keep tabs on and protect physical assets from the moment they’re … [Read more…]

2022 User Satisfaction Survey names Veradigm Payerpath the top solution for End-To-End RCM Software Technology, supporting Physicians Practices & Ambulatory Facilities/Groups CHICAGO–(BUSINESS WIRE)–$MDRX #healthIT—Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), today announced that Black Book, a healthcare-centric market research and public opinion … [Read more…]

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation to highlight updated results from phase 1/2 trial of DS-7300 in several types of cancer including lung, esophageal and prostate MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: … [Read more…]

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern Time on Wednesday, September 28, 2022, focusing on Hybrid AF Therapy. The webcast will include … [Read more…]

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster … [Read more…]

Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer CHICAGO–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical … [Read more…]